The clinical and economic burden of idiopathic hypersomnia: a plain language summary of publication
Plain Language SummaryWhat is this summary about?This plain language summary explains what two studies found about the comorbidity and financial impact that people with idiopathic hypersomnia may experience.One article was published in the journal Nature and Science of Sleep and studied how often people with idiopathic hypersomnia have other health conditions (including heart and mental health conditions), how they used medical care, and the costs of their overall healthcare. The article compared people diagnosed with idiopathic hypersomnia to people without idiopathic hypersomnia.The other article was published in the journal Sleep Medicine and studied how often people with and without idiopathic hypersomnia had a broad array of different cardiovascular health conditions.What were the results?In this study, a higher percentage of people with idiopathic hypersomnia had other health conditions, including cardiovascular, cardiometabolic, and neuropsychiatric conditions compared to people without idiopathic hypersomnia with similar characteristics (e.g., age, gender, geographic region, insurance type).Additionally, people with idiopathic hypersomnia used medical care more often and had higher costs for medical care.What do the results mean?A higher percentage of people with idiopathic hypersomnia in this study experienced health conditions (including cardiovascular, cardiometabolic, and neuropsychiatric conditions) in addition to their idiopathic hypersomnia compared with people who did not have idiopathic hypersomnia.In addition, people with idiopathic hypersomnia received health care more often and had higher medical costs.People with idiopathic hypersomnia may consider their overall health and ways to improve their health through lifestyle changes, and health professionals may wish to consider their patients’ overall, whole-person health when choosing medicines to treat their idiopathic hypersomnia.How to say (download PDF and double click sound icon to play sound)…Apnea: AP-nee-uhAtrial fibrillation: AY-tree-uhl fi-bruh-LAY-shunCardiometabolic: KAAR-dee-oh-meh-tuh-BAA-likCardiovascular: KAAR-dee-oh-VAS-kyoo-luhrComorbidity: kow-mor-BI-duh-teeCoronary revascularization: KAWR-uh-nehr-ee ree-va-skuh-lr-ai-ZAY-shnEdema: eh-DEE-mahHyperlipidemia: hai-per-li-puh-DEE-mee-uhHypersomnia: hai-per-SAAM-nee-uhIdiopathic: i-dee-uh-PA-thikNeuropsychiatric: nur-oh-sai-kee-A-trikComorbidity: Other health problems that occur along with idiopathic hypersomnia.Idiopathic hypersomnia: A sleep disorder that can cause people to be very sleepy throughout the day, even if they had a full night of sleep the night before. The cause of this sleep disorder is unknown.Cardiovascular: Relating to the heart and blood vessels.Cardiometabolic: Relating to both cardiovascular and metabolic conditions, such as diabetes and obesity.Neuropsychiatric: Relating to conditions that involve the brain and mental health.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink both original articles (here and here).
Authors
- D. Profant (ORCID: https://orcid.org/0000-0003-4323-9348)
- Weiyi Ni (ORCID: https://orcid.org/0000-0003-4244-0699)
- Sarah Coseo Markt (ORCID: https://orcid.org/0000-0003-2873-0358)
- Elizabeth M. Poole (ORCID: https://orcid.org/0000-0002-4680-4587)
- Douglas S. Fuller (ORCID: https://orcid.org/0000-0002-2448-5896)
- Patricia Prince (ORCID: https://orcid.org/0000-0002-0705-6942)
- Shaina Desai (ORCID: https://orcid.org/0000-0003-2497-4777)
- Jed Black
- M Whalen
- Caitlin Dilley (ORCID: https://orcid.org/0000-0001-6400-6864)
Institutions
- Jazz Pharmaceuticals (United States) (US)
- Aetion (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Future Neurology
- Published
- 2026-06-09
- DOI
- https://doi.org/10.1080/14796708.2026.2674550
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jazz Pharmaceuticals